当前位置: X-MOL 学术Nature › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
Nature ( IF 64.8 ) Pub Date : 2021-06-23 , DOI: 10.1038/s41586-021-03732-8
Jingyou Yu 1 , Lisa H Tostanoski 1 , Noe B Mercado 1 , Katherine McMahan 1 , Jinyan Liu 1 , Catherine Jacob-Dolan 1, 2 , Abishek Chandrashekar 1 , Caroline Atyeo 2, 3 , David R Martinez 4 , Tochi Anioke 1 , Esther A Bondzie 1 , Aiquan Chang 1, 2 , Sarah Gardner 1 , Victoria M Giffin 1 , David L Hope 1 , Felix Nampanya 1 , Joseph Nkolola 1 , Shivani Patel 1 , Owen Sanborn 1 , Daniel Sellers 1 , Huahua Wan 1 , Tammy Hayes 5 , Katherine Bauer 5 , Laurent Pessaint 6 , Daniel Valentin 6 , Zack Flinchbaugh 6 , Renita Brown 6 , Anthony Cook 6 , Deandre Bueno-Wilkerson 6 , Elyse Teow 6 , Hanne Andersen 6 , Mark G Lewis 6 , Amanda J Martinot 5 , Ralph S Baric 4 , Galit Alter 3 , Frank Wegmann 7 , Roland Zahn 7 , Hanneke Schuitemaker 7 , Dan H Barouch 1, 2, 3
Affiliation  

The emergence of SARS-CoV-2 variants that partially evade neutralizing antibodies poses a threat to the efficacy of current COVID-19 vaccines1,2. The Ad26.COV2.S vaccine expresses a stabilized spike protein from the WA1/2020 strain of SARS-CoV-2, and has recently demonstrated protective efficacy against symptomatic COVID-19 in humans in several geographical regions—including in South Africa, where 95% of sequenced viruses in cases of COVID-19 were the B.1.351 variant3. Here we show that Ad26.COV2.S elicits humoral and cellular immune responses that cross-react with the B.1.351 variant and protects against B.1.351 challenge in rhesus macaques. Ad26.COV2.S induced lower binding and neutralizing antibodies against B.1.351 as compared to WA1/2020, but elicited comparable CD8 and CD4 T cell responses against the WA1/2020, B.1.351, B.1.1.7, P.1 and CAL.20C variants. B.1.351 infection of control rhesus macaques resulted in higher levels of virus replication in bronchoalveolar lavage and nasal swabs than did WA1/2020 infection. Ad26.COV2.S provided robust protection against both WA1/2020 and B.1.351, although we observed higher levels of virus in vaccinated macaques after B.1.351 challenge. These data demonstrate that Ad26.COV2.S provided robust protection against B.1.351 challenge in rhesus macaques. Our findings have important implications for vaccine control of SARS-CoV-2 variants of concern.



中文翻译:

Ad26.COV2.S 对猕猴 SARS-CoV-2 B.1.351 的保护作用

部分逃避中和抗体的 SARS-CoV-2 变体的出现对当前 COVID-19 疫苗1,2的功效构成威胁。Ad26.COV2.S 疫苗表达来自 SARS-CoV-2 WA1/2020 毒株的稳定刺突蛋白,最近在几个地理区域(包括南非,其中 95 COVID-19 病例中测序病毒的百分比是 B.1.351 变体3. 在这里,我们显示 Ad26.COV2.S 引发与 B.1.351 变体交叉反应的体液和细胞免疫反应,并保护恒河猴免受 B.1.351 攻击。与 WA1/2020 相比,Ad26.COV2.S 诱导了针对 B.1.351 的较低结合和中和抗体,但引发了针对 WA1/2020、B.1.351、B.1.1.7、P.1 的相当的 CD8 和 CD4 T 细胞反应和 CAL.20C 变体。B.1.351 控制恒河猴感染导致支气管肺泡灌洗液和鼻拭子中病毒复制水平高于 WA1/2020 感染。Ad26.COV2.S 提供了针对 WA1/2020 和 B.1.351 的强大保护,尽管我们在 B.1.351 攻击后观察到接种疫苗的猕猴中的病毒水平更高。这些数据表明,Ad26.COV2.S 在恒河猴中提供了针对 B.1.351 攻击的强大保护。

更新日期:2021-06-23
down
wechat
bug